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Abstract
The chemokine receptor CXCR4 is shared by primary and laboratory-adapted strains of feline immunodeficiency virus (FIV)
for viral entry. Our previous studies implicated a contiguous nine-amino-acid region of the V3 loop of the FIV envelope
surface as important in CXCR4 binding and virus entry. The binding is specific for CXCR4 since it can be inhibited by
AMD3100, a selective CXCR4 inhibitor. Additional site-directed mutagenesis was used to further reveal the key residues.
Binding studies indicated that basic residues R395, K397, R399 as well as N398 are critical for CXCR4 binding. The effect of
other amino acid residues on receptor binding depends on the type of amino acid residue substituted. The binding study
results were confirmed on human CXCR4-expressing SupT1 cells and correlated with entry efficiency using a virus entry
assay. Amino acid residues critical for CXCR4 are not critical for interactions with the primary binding receptor CD134, which
has an equivalent role as CD4 for HIV-1 binding. The ELISA results show that W394 and W400 are crucial for the recognition
by neutralizing anti-V3 antibodies. Since certain strains of HIV-1 also use CXCR4 as the entry receptor, the findings make the
feline model attractive for development of broad-based entry antagonists and for study of the molecular mechanism of
receptor/virus interactions.
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Introduction
Feline immunodeficiency virus (FIV) is the only nonprimate
lentivirus that causes an AIDS-like disease in its natural host, the
domestic cat [1]. Thus, FIV infection in cats has been established
as a valuable animal model for the development of anti-retroviral
agents against lentivirus including HIV, and study of lentiviral
pathogenesis [2–5]. In regard to receptor usage, the two
lentiviruses have a common mechanism, but they act through
distinct binding receptors. HIV-1 uses CD4 as a primary binding
receptor, whereas FIV utilizes CD134 [6,7]. After interaction with
the primary binding receptor [8,9], however, FIV (primary and
laboratory-adapted FIV strains [10]) and T-cell tropic HIV-1
strains both utilize the chemokine receptor CXCR4 as the entry
receptor. The predicted amino acid sequence of feline CXCR4
displays 94.9% identity to human CXCR4, with the majority of
the differences located in the N-terminus and the second
extracellular loop [8]. In addition, it has been reported that the
second extracellular loop of CXCR4 contains a critical determi-
nant for the function of CXCR4 as a receptor for infection with
FIV [11,12]. Both human and feline CXCR4 have a number of
negative charges at the extracellular surface [8,13–16].
In contrast to the negative charged extracellular surface of
CXCR4, the hypervariable region 3 (V3 loop) of HIV-1 is
positively charged and binds to the surface of the receptor in the
N-terminal extracellular loop [17]. HIV-1 V3 typically consists of
35 amino acids (range 31 to 39) and is functionally important [18].
The HIV-1 V3 loop has been previously termed as the ‘‘principal
neutralizing determinant’’ of HIV-1, since many HIV-1 neutral-
izing antibodies from infected individuals target this region of
gp120 [19]. Such antibodies prevent the binding of gp120 to the
chemokine receptors and thus block the events leading to viral
fusion [20,21]. The findings indicate that the V3 amino acid
sequence determines whether the virus binds to CCR5 (‘‘R5
phenotype’’) as a predominantly macrophage-tropic isolate, or to
CXCR4 (‘‘X4 phenotype’’), which are primarily T cell-tropic
isolates [20–22]. Moreover, the presence of a basic residue at V3
positions 306 or 322 is associated with X4 and dual-tropic
phenotype (X4R5 viruses), whereas the presence of a neutral
residue and a negatively charged residue at positions 306 and 322,
respectively, is correlated with R5 viruses (the ‘‘11/25 rule’’) [23].
Then, a new ‘‘11/24/25 rule’’ updates that: positively charged
amino acids at positions 11, 24, or 25 define X4; otherwise the
virus has a R5 phenotype [24]. Thus, the V3 loop is a primary
target for HIV-1 entry inhibitors that are being developed as
antiviral drugs [18].
Although the envelope glycoproteins of FIV and T-cell tropic
HIV-1 share only minor sequence identity in SU, there are analogies
in the location and distribution of the SU variable regions V3-V5
[25–30]. Although the consensus sequences of conserved cysteine
residues between both viruses display a low degree of homology, there
stillexistsome similarities. First, the FIV V3 loop has an approximate
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10689Figure 1. Identification of receptor expression on the cell surface and SU binding to cells of 3201, SupT1, 104-C1 and Gfox,
respectively, detected by FACS analysis. The detection of CXCR4 and CD134 was carried out by using CXCR4 or CD134-specific antibody,
followed by anti-mouse (CXCR4) or anti-rabbit (CD134) IgG conjugated with phycoerythrin. Binding of FIV SU-Fc to cells was measured by using a
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both FIV and HIV V3 regions arepositivelycharged [9,18,24,31,32].
A JPRED analysis predicts the secondary structure of the V3 loops of
both viruses as to display a high degree of similarity. Furthermore,
both V3 loops are predicted to have a relatively conserved centrally
located tip flanked by two beta sheets [33,34]. Finally, the consensus
s e q u e n c eo ft h eH I V - 1V 3t i pi sar e l a t i v e l yc o n s e r v e dG P G Ro r
GPGQ [18]. Similarly, the amino acids at the tip of FIV V3 (namely
the ‘‘N44 region’’ we describe in the present study) are conserved
across strains, including two tryptophans (98 and 100% conserved,
respectively), one lysine (55% conserved), and two arginines that are
73% and 99% conserved, respectively. The domain and amino acid
residues of HIV-1 involved in CXCR4 binding have been clearly
identified [17,18,24,31,32,35], however, amino acid residues critical
for SU/CXCR4 interacts with FIV still require mapping.
Our previous binding studies using SU-Fc deletion mutants and
SU- specific monoclonal antibodies strongly support the involvement
o ft h eV 3l o o po fS Ui nt h eF I V - C X C R 4i n t e r a c t i o n .F u r t h e r m o r e ,a
contiguous nine-amino-acid region (SSWRQKNRW, designated
N44) of FIV V3 is a neutralization target for CD134-dependent virus
neutralization via blocking CXCR4 binding and virus entry [36].
The purpose of this study was to define the key amino acid
residues required for CXCR4 binding and establish the relation-
ship between binding and entry. We created a series of SU
mutants by site-directed mutagenesis to introduce amino acid
substitutions in the N44 region, together with a panel of V3-
specific antibodies and then used these mutants to define residues
critical for CXCR4 interaction.
Results
Detection of CD134 or CXCR4 expression in cell lines
To characterize the receptor binding properties of wild type and
mutated FIV PPR SUs, we used a series of continuous and
engineered cell lines (Figure 1). Fluorescence activated cell sorting
(FACS) analysis of the cell surface expression of CD134 and
CXCR4 showed that 3201 cells expressed relatively high levels of
CXCR4 but were negative for CD134 (Figure 1A, left panel). FIV
PPR SU-Fc bound strongly to 3201, but the binding was inhibited
when pretreated with CXCR4 inhibitor AMD3100 (Figure 1A,
right panel). For SupT1 cells which express human CXCR4 [37],
we utilized a human specific anti-CXCR4 antibody, 12G5, which
does not recognize feline CXCR4 [38–40]. SupT1 cells also
expressed CXCR4 at a high level (Figure 1B, left panel) and PPR
SU bound strongly to the human homologue, and the binding was
competed by AMD3100 (Figure 1B, right panel). Remarkably,
human CXCR4 is a more efficient receptor for FIV than either
feline CXCR4 or rat CXCR4 [11]. By contrast, 104-C1 cells
expressed a high level of CD134 but a low concentration of
CXCR4 (Figure 1C, left panel). FIV-PPR SU bound well to this
cell line via CD134 with no evident blocking by AMD3100
(Figure 1C, right panel), which is consistent with previous reports
[6,9,41]. Gfox cells are CrFK cells that have been engineered to
over-express CD134 [6]. Our results showed that feline CD134
was observed (Figure 1D, left panel) and SU-Fc specifically
interacted with feline CD134 (Figure 1D, right panel). CXCR4
appeared insignificant on these cells (Figure 1D, left panel).
However, Gfox cells are infectable with FIV field strains and
infection is blocked by AMD3100, consistent with entry by
CXCR4 expression [6]. Also, CrFK cells express CXCR4 RNA
[8] and our quantitative real time PCR results indicated that Gfox
cells express CXCR4 mRNA at levels comparable to CrFK cells
(data not shown).
Characterization of feline anti-CXCR4 antibody
The feline anti-CXCR4 antibody used in the present study had
no cross-reactivity with human CXCR4 (Figure 1B, left panel). To
determine whether the binding region of anti-CXCR4 antibody
corresponded to CXCR4-binding domain for SU, we performed
competition binding assay in 3201 cells. FACS analysis showed
that AMD3100 did not block anti-CXCR4 antibody binding to
3201 cells and the antibody did not inhibit SU-Fc binding to 3201
cells (Figure 2), indicating the recognition epitope for the antibody
was distinct from the binding site for SU.
V3 is the major binding domain of SU for CXCR4 in 3201
cells
Our previous study using SU-Fc adhesins with deletion mutants of
V2, V3, V4 or V5 showed that SU-Fc mutants with deletion of V2,
V4 or V5 retained the ability to bind CXCR4. In contrast, the V3-
deleted SU-Fc failed to bind 3201 cells [36]. Thus, the V3 region is
critical for SU binding to CXCR4. Here, we utilized the His-tagged
V3 peptide (Figure 3) to directly confirm the role of V3 region for
CXCR4 binding in competition studies (Figure 4). The sequence of
the V3 peptide and the linear binding epitopes for six anti-V3
antibodies are shown on Figure 3. FACS analysis showed that the V3
peptidecouldantagonizefull-lengthSU-Fcbindingto3201cells.Ata
comparable concentration as SU, the V3 peptide almost completely
blocked the SU binding to 3201 cells (Figure 4A), and markedly
reduced the binding of SU to human CXCR4 on SupT1 cells
(Figure 4B). The peptide had negligible effect on SU binding to 104-
C1 (Figure 4C) or Gfox cells (Figure 4D) (i.e., to CD134).
Construction and expression of FIV-PPR SU-Fc mutants
Our analyses by using V3 deletion mutants, V3-specific mAbs,
and V3 peptide strongly support the involvement of SU V3 in the
FIV-CXCR4 interaction. We next sought to determine the
minimal domain within the V3 region required for SU-CXCR4
interaction. Since a peptide as short as nine amino acids
(SSWKQRNRW) designated N44, was potent in blocking SU
binding [36], we evaluated a number of amino acid substituted
mutants in the N44 region of FIV PPR SU to further reveal the
key residues. Our mutagenic analysis employed a series of
conservative or non-conservative changes, and so was used to
assess the binding phenotypes induced by residues present in other
FIV isolates (Figure 5A). In addition, either alanine substitutions or
mutations likely to disrupt (non-conserved replacement) or imitate
(conserved alteration) interactions were substituted (Figure 5B).
SU-Fc constructs were generated by site-directed mutagenesis and
soluble proteins were produced from CHO cell lines. All purified
SU-Fc proteins were quantified by ELISA, and then subjected to
SDS-PAGE and western blotting (using anti-human IgG1 Fc
antibody) to confirm the expected size and relative quantitation of
each mutant (Figure 5B).
Fine mapping of the V3 region required for interaction
with CXCR4
Binding affinity assays by FACS were performed using 3201,
SupT1, and 104-C1 cells as described as ‘‘Material and Methods’’.
phycoerythrin-conjugated anti-Fc antibody, in the presence and absence of the CXCR4 antagonist AMD3100. Cells were incubated with SU-Fc or pre-
treated with AMD3100 for 30 min prior to the addition of SU-Fc. Results are representative of three independent determinations.
doi:10.1371/journal.pone.0010689.g001
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to 100%, and the binding data for specifically constructed mutants
were normalized to this value. The results are summarized in
Table 1, Table 2, Table 3.
As seen from table1 (using 3201 cells) or table 2 (using SupT1
cells), the binding of FIV PPR SU-Fcs to 3201 and SupT1 cells is
specific for CXCR4 since it can be inhibited by AMD3100 in a
dose-dependent manner. In 3201 cells, alanine substitutions
introduced into residues S392 and S393 did not significantly
affect the binding of SU mutants to CXCR4, whereas introduction
of methionine (S392M or S393M) dramatically reduced CXCR4
binding. By contrast, the more conservative introduction of
threonine at the same sites affected CXCR4 binding much less.
W394A partially abolished the CXCR4 binding affinity. A triple-
alanine substituted mutant S392A/S393A/W394A decreased the
binding efficiency to less than 40%. The mutant W394G or
W394Y also reduced the CXCR4-binding affinity at a similar level
to W394A. Although W400 and W394 are similarly conserved
among FIV isolates, mutant W400G, together with W394G/
W400G, exhibited specific defects in the ability to bind CXCR4,
which indicates that W400 is more sensitive than W394 to the
same substitution of glycine. However, when W400 was changed
to Y400, the reduction of binding affinity was minimal. Overall,
the results suggest that residue W400 requires some steric effect for
CXCR4 binding which is accommodated by aromatic amino acids
in general. Amino acid substitutions by the same kinds of basic
residues kept the same binding capacities as wild type or binding
was mildly enhanced, as seen with R395K, K397R, and R395K/
K397R. An exception was an R399K substitution, which
completely abolished SU binding. However, when basic residue
R395 was replaced by a non-basic residue, R395N, the mutant lost
the binding efficiency. Interestingly, mutant SU with substitution
of Q396N retained the binding affinity to CXCR4, whereas,
alteration of N398Q completely abrogated CXCR4 binding
ability, although both residues were replaced by the same
character of amino acid residue. Based on the data, we can
Figure 2. Analysis of inhibition of feline CXCR4 antibody binding to 3201 cells by pretreatment with AMD3100(left panel) or
blockade of SU binding to 3201 cells by pretreatment with fCXCR4 mAb (right panel). Results are representative of three independent
determinations.
doi:10.1371/journal.pone.0010689.g002
Figure 3. Sequence of His-tagged PPR V3 peptide and binding sites of anti-V3 antibodies on the V3 loop of FIV SU. Red box indicates
6XHis. The amino acids are numbered according to the sequence of the V3 loop of PPR SU, and the V3 loop is bordered by cysteine (C), which is
underlined. N44 region of V3 loop is indicated in bold. Linear binding sites of V3 antibodies SU1-5, SU1-10, SU1-30, SU2-4, SU2-5 and SU2-10 are
indicated respectively. SU1-7 is not shown due to its conformation dependence.
doi:10.1371/journal.pone.0010689.g003
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CXCR4 binding. S392, S393, W394 and W400 also affect the
binding, but the effects at these latter positions depend on the
nature of the amino acid substitution. None of the amino acid
substitutions significantly increased SU binding to CXCR4,
although the mutant of S393A caused a slight enhancement of
approximately 10%.
Similar trends were noted in the binding efficiencies of the panel
of mutant SU to human CXCR4 on SupT1 cells (Table 2).
However, certain sites caused greater reductions in binding to the
human homologue than to feline CXCR4 (compare values,
Tables 1 and 2). In particular, S392T and W394G mutations
caused greater loss of binding to human than feline CXCR4 (bold
values, Table 2), with reductions of 90–100% compared to 40–
60% reduction to feline CXCR4 (Table 1).
Amino acid residues critical for CXCR4 binding were less
crucial for interactions with the primary binding receptor CD134,
i.e., the above amino acid substitutions had a more global effect on
binding to CD134 on 104-C1 cells, with approximately 20-50%
reduction in SU binding irrespective of amino acid substitutions at
sites critical for CXCR4 binding (Table 3). Therefore, it appears
that the V3 loop, particularly its ‘‘N44 region’’, is directly required
for interaction of SU with the entry receptor CXCR4 but not with
the binding receptor CD134. The results indicate that the binding
of CD134 is heavily dependent on the overall conformation of SU
rather than on a short contiguous epitopes as with CXCR4.
Infectivity assay using pseudotyped FIV
To confirm that SU binding is directly related to the entry
efficiency, a virus entry assay was performed in Gfox cells. b-
galactosidase-expressing vectors were pseudotyped with FIV-PPR
SUs replaced by the same amino acid substitutions described
above and used for production of virions in 293T cells. After
normalizing the virus supernatants for RT activity, the pseudovir-
ions were then used in single-round virus entry assays in Gfox cells
[6]. Introduction of alanine at S392 had no effect, but the same
substitution at S393 or W394 (or the triplet S392/S393/W394)
partially abrogated the ability of the mutant SU to facilitate virus
entry into Gfox cells (entry ratios between 35%–60%, compared
with wild type, Figure 6). The alteration of S393M essentially
abrogated virus entry while S392M retained modest entry
capacities. S392T and S393T mutants entered the cells at levels
comparable to wild type SU, with entry ratios of 80% and 115%,
respectively. The alteration of W394G decreased the efficiency of
viral entry in Gfox cells, whereas, W394Y infected at 118% of wild
type levels. The mutants R395K, R395K/K397R, Q396N and
K397R infected at wild type levels, with a slight increase.
However, N398Q and R399K caused almost complete loss of
ability to enter the cells. The substitution of W400G and W394G/
W400G blocked the ability of the mutant SU to facilitate virus
entry into Gfox cells, while mutant W400Y could enter the cells.
Surprisingly, although the mutant of R395N exhibited a severe
reduction in CXCR4-binding ability, the change in this residue
exerted only little effect on virus entry. Another exception was
S393A, which retained SU binding abilities (Table 1), but
performed poorly in the entry assay (Figure 6). Compared with
the CXCR4 binding affinities, S392M, S392T, W394Y and
W400G increased entry capacities to some extent, but they still
had weak entry efficiencies or had a mild change.
Figure 4. Inhibition of SU-Fc binding to 3201, SupT1, 104-C1
and Gfox cells by His-tagged V3 peptide. The peptide was pre-
incubated with the cells for 1 h before the addition of SU-Fc to cells and
incubated for another 1 h at room temperature. SU-Fc binding was
detected by anti-Fc antibody and analyzed by FACS. V3 peptide blocks
SU-Fc binding to 3201 and SupT1 cells, but has little effect on 104-C1
and Gfox cells. Results are representative of three independent
determinations.
doi:10.1371/journal.pone.0010689.g004
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to SU
To further characterize the binding sites of V3-specific
neutralizing monoclonal antibodies (mAbs) generated by immu-
nizing mice with SU-Fc [36,42,43], ELISA assays were performed
with the same set of SU-Fc proteins used in the binding studies
(Table 4, Table 5). All of the mutants interacted with the SU1-5
and SU1-10 mAbs comparably to that of the wild-type SU,
consistent with the binding epitopes of these antibodies being
outside N44 region. SU1-7 was a conformation dependent
antibody, which could not be recognized by mutants R399K,
W400G and W394GW400G. The affinity of SU 1-30 for all of
W394 mutants was dramatically reduced, while the other mutants
bound similarly to wild type SU, indicating that W394 is a key
residue for the epitope recognized by SU 1-30 (Table 4). W400
was important for the recognition of SU2-4 and SU2-5. Also, two
mutants with the change of tryptophan to glycine (W400G and
W394G/W400G) were not recognized by SU2-4 or SU2-5.
However, the binding abilities of these antibodies were 45–60%
restored when this residue was replaced by tyrosine, a similar
situation that had been observed in the binding studies. The
binding affinity of SU2-10 for the W400G and W394GW400G
was modestly reduced, indicating W400 also had some effect on
the recognition of the antibody (Table 5). These results suggest
that the recognition of V3 antibodies for some mutants is specific
and neutralizing antibody-sensitive epitopes are located in the
CXCR4 binding sites. Highly conserved residues W394 and W400
play an important role in the recognition by antibodies. The
findings emphasize that FIV neutralizing antibodies recognize the
CXCR4 binding region of SU or epitopes or in very close
proximity to this domain.
Discussion
Our previous studies defined a nine-amino acid domain at the
tip of the V3 loop of FIV SU as critical for the interaction with
CXCR4 [36]. In this report, we further define the key amino acid
residues required for CXCR4 binding and establish the relation-
ship between binding and entry. Site-directed mutagenesis was
employed to introduce amino acid substitutions in the N44 region
with residues that are found in other FIV isolates as well as
changes that may influence CXCR4 binding. The panel of
mutants was further utilized to define residues critical for
neutralizing antibodies that recognize the V3 domain. In addition,
using the binding assay in conjunction with a panel of receptor-
Figure 5. (A). Sequences and amino acid percent frequency of the ‘‘N44 region’’ of FIV isolates. The number next to each residue
indicates the frequency at which the corresponding residue is found among over 200 FIV envelope sequences published in Genbank. (B) Expression
of FIV SU-Fc with amino acid substitutions. FIV SU-Fc mutants were generated by site-directed mutagenesis, expressed by stable transfection of
CHO-K1 cells and batch purified from cell supernatants by affinity chromatography over protein A-Sepharose. 100 ng of SU-Fc (wt and mutants) were
subjected to SDS-PAGE under reducing conditions and reacted with HRP-conjugated anti-human IgG1antibody. The labels are located above in
which amino acid substitutions have been introduced, and the resulting mutants were assessed for abilities to bind CXCR4 and CD134.
doi:10.1371/journal.pone.0010689.g005
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CXCR4 and CD134. 3201 cells lack CD134 and heparan sulfate
proteoglycans (HSPG) expression, so the use of 3201 in binding
assays allows the evaluation of specific SU-CXCR4 interactions
[41]. The 104-C1 continuous cell line is CD134
high and
CXCR4
low, which provides a venue to assess SU-CD134
interactions. Human CXCR4-expressing SupT1 cells were used
to confirm the interactions of SU and CXCR4, based on the
agreement of the high degree of homology between CXCR4 of
feline and human origins [8]. Interestingly, human CXCR4 is a
more efficient receptor for FIV than either feline CXCR4 or rat
CXCR4 and was in fact employed in the original study that
showed CXCR4 was the entry receptor for FIV [11].
Our results demonstrate several amino acid residues in the V3
loop make key contributions to CXCR4 binding. These key
positions primarily consist of basic and aromatic residues. For
HIV-1, some basic residues on the V3 loop likely contribute to
electrostatic interactions and the formation of specific salt bridges
with CXCR4 [35,44], which is acidic at the N-terminus and in
extracellular loops [13]. In addition, conserved hydrophobic
residues in the V3 loop of HIV gp120, especially at the tip/crown
of HIV V3, have been shown to contribute to CXCR4 binding
[35]. Similarly, the N44 region in the FIV V3 loop includes three
basic residues and two aromatic tryptophan residues among over
200 FIV envelope sequences published in Genbank. Essentially
invariant in the majority of FIV envelope sequences, these three
basic residues R395, K397, and R399 exhibit a limited number of
conservative substitutions. Arginine or lysine is found at residues
395 and 397, although some non-charged or negative-charged
residues are also found at the analogous position (Figure 5A).
Consistent with a role for basic residues in CXCR4 binding, the
mutants R395K, K397R, and R395K/K397R kept the same
binding capacities as wild type or enhanced lightly in 3201 cells. In
contrast, asparagine substitution introduced into R395 significant-
ly blocked the binding of SU to CXCR4, indicating that
electrostatic attraction plays an important role for CXCR4
binding with this residue. To our surprise, mutant R395N did
not prevent virus entry into the Gfox cells, in spite of the
observation that this mutant markedly reduced CXCR4 binding.
We assume that there is some difference between dimeric SU-Fc in
the context of a dimeric immunoadhesin and trimeric SU on the
virus particle. Thus, the alteration of R395N in the V3 loop of FIV
PPR allows this virus to utilize CXCR4 for entry into target cells
under certain circumstances. Interestingly, arginine at residue 399
Table 1. Effects of Amino Acid Substitutions in SU on CXCR4-
binding Ability in 3201 Cells.
PPR SU variants AMD 3100
- 0.03 mg/ml 0.1 mg/ml 0.3 mg/ml
Mock 0.160.1 - - -
Wild type 100.060.0 33.662.8 9.062.1 1.060.6
S392A 102.760.1 36.2610.5 9.263.8 1.060.0
S392M 7 7.260.1 0.960.0 0.160.0 0.160.1
S392T 41.363.9 5.463.6 0.560.0 0.360.0
S393A 109.568.8 56.261.0 25.763.8 6.560.2
S393M 0 0.260.1 0.060.1 0.060.1 0.460.4
S393T 74.166.0 28.067.0 6.060.4 0.460.0
W394A 63.4610.9 18.260.5 2.760.4 0.260.1
W394G 52.067.3 16.061.2 1.760.0 0.060.0
W394Y 63.461.6 16.863.4 4.260.0 0.260.0
S392A/S393A/W394A 35.269.3 4.160.6 0.260.0 1.062.0
R395K 103.762.0 32.366.4 11.664.5 3.560.3
R395N 6 6.560.7 1.360.3 0.460.2 0.260.1
Q396N 97.662.6 38.866.3 12.461.6 1.460.1
K397R 92.061.1 21.169.2 7.163.8 1.660.0
R395K/K397R 104.966.1 54.466.2 21.461.4 2.660.6
N398Q 0 0.460.0 0.760.7 0.260.1 0.260.0
R399K 0 0.060.1 0.060.2 0.060.2 0.160.1
W400G 5 5.461.1 0.260.1 0.060.1 0.060.1
W400Y 88.663.5 28.864.5 9.262.8 1.060.6
W394G/W400G 3 3.660.6 3.561.2 1.960.2 3.860.3
a. Binding of FIV PPR SU-Fc of wild type and mutants to 3201 was analyzed by
FACS in the presence and absence of AMD3100. Cells were incubated with SU-
Fc of wild type or mutants for 1 h at the room temperature or pre-treated with
AMD3100 for 0.5 h before the addition of SU-Fc. Results are indicated as
mean6SD of three independent determinations. Values for mutants are
percentages of the mean fluorescence intensity of wild type SU, which is
regarded as 100%.
b. Values in bold represent loss of specific antibody reactivity to a given mutant.
doi:10.1371/journal.pone.0010689.t001
Table 2. Effects of Amino Acid Substitutions in SU on CXCR4-
binding Ability in SupT1 Cells.
PPR SU variants AMD 3100
- 0.01 mg/ml 0.03 mg/ml 0.1 mg/ml
Mock 0.160.0 - - -
Wild type 100.060.0 61.469.8 31.069.8 8.566.8
S392A 67.060.2 46.868.0 14.260.4 0.960.2
S392M 0 0.260.1 0.060.0 0.060.0 0.060.0
S392T 2 2.260.3 0.760.2 0.660.0 0.560.1
S393A 93.661.0 60.761.3 18.764.6 1.761.1
S393M 0 0.260.1 0.160.0 0.160.0 0.260.0
S393T 46.260.6 16.560.2 1.560.5 0.260.0
W394A 15.863.9 3.761.2 0.660.1 0.360.1
W394G 9 9.660.5 2.760.7 0.360.0 0.260.1
W394Y 32.562.1 14.160.2 1.260.4 0.460.0
S392A/S393A/W394A 6 6.062.6 2.561.9 1.060.6 0.560.4
R395K 99.261.2 67.361.7 38.360.7 6.762.2
R395N 7 7.860.4 2.160.9 0.260.2 0.160.0
Q396N 84.265.2 57.762.2 29.863.5 4.160.6
K397R 64.262.3 39.165.0 19.760.4 3.063.2
R395K/K397R 103.863.6 75.860.4 45.565.8 16.360.6
N398Q 0 0.260.0 0.460.4 0.160.0 0.260.0
R399K 0 0.260.3 0.260.3 0.060.0 0.060.0
W400G 0 0.260.0 0.360.0 0.260.0 0.260.0
W400Y 91.362.1 60.964.7 20.165.6 1.761.0
W394G/W400G 9 9.160.8 2.760.10 0.860.6 0.760.6
a. Binding of FIV PPR SU-Fc of wild type and mutants to SupT1 was analyzed by
FACS in the presence and absence of AMD3100. Cells were incubated with SU-
Fc of wild type or mutants for 1 h at the room temperature or pre-treated with
AMD3100 for 0.5 h before the addition of SU-Fc. Results are indicated as
mean6SD of three independent determinations. Values for mutants are
percentages of the mean fluorescence intensity of wild type SU, which is
regarded as 100%.
b. Values in bold represent loss of specific antibody reactivity to a given mutant.
doi:10.1371/journal.pone.0010689.t002
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with even a conservative substitution of R399K resulting in
disruption of CXCR4 binding and abrogation of virus entry. One
interpretation of the results is that the loss of favorable CXCR4
interactions with this residue has been impacted by a steric effect
much more than the electrostatic attraction.
Among the three basic residues are two polar uncharged amino
acid residues, Q396 and N398. Of interest, substitution of Q396N
maintained the binding affinity to CXCR4, whereas, replacement
of N398Q dramatically abolished CXCR4 binding. Thus, it
appears that steric effects have a substantial influence at these two
residues with intolerance to conserved amino acid changes.
Two highly conserved tryptophan residues at positions 394 and
400 are found with the frequency of 98% (glycine is 2%) and
100%, respectively. When glycine was introduced into these two
positions separately or combined, the mutant SU-Fc of W394G
partially reduced the binding ability, whereas, W400G and
W394G/W400G mutants were significantly attenuated. More-
over, the latter two mutants were not recognized efficiently by the
SU1-7, SU2-4 and SU2-5 mAbs, consistent with previous studies
indicating the involvement of W400 in the epitopes for the
antibodies [36,42,43]. However, some tyrosine substitutions,
although involving these two highly conserved positions, did not
significantly modify the binding affinity to CXCR4 or capacity to
enter Gfox cells. It appears that aromatic residues have a similar
steric effect so that the conformation of V3 loop is preserved by a
conservative substitution.
Other positions were relatively tolerant to conserved amino acid
changes, but not to changes that substantially alter amino acid
character. Alanine substitution for serine at positions 392 and 393
did not abolish SU binding to CXCR4, but the change to
methionine dramatically reduced CXCR4 binding in both 3201
and SupT1 cells. When triple-alanine substitutions were intro-
duced into positions 392, 393 and 394, the binding efficiency
decreased to less than 40%, which suggests that these residues may
contribute directly or indirectly to maintenance of a continuous
surface for CXCR4 binding. Correspondingly, the effect of the
threonine substitution at position 392 on CXCR4 binding was
much more severe than that of alteration at position 393. Thus,
serine at 392 may be more important for CXCR4 binding than at
393.
The present studies also show that the same set of N44 region
mutants did not abrogate binding to the primary binding receptor
CD134 on 104-C1 cells. Rather, all changes had a negative impact
on CD134 binding. The results indicate that binding of SU to
CD134 is highly conformation dependent, consistent with the
inability in this study or in previous efforts [36] to define one
distinct binding domain. Since the Gfox cell line expresses both
CD134 and CXCR4, it may well be that some of the reduction
observed in the CD134 binding assay for some mutants may also
contribute to reduced infectivity observed in figure 6. However,
the reduction of infectivity correlates well with loss of CXCR4
binding; i.e., we do not see loss in infectivity with any mutant that
did not lose CXCR4 binding ability, which one would expect if the
mutation primarily impacted on CD134 association and therefore
caused loss in infectivity.
Although the V3 loop of SU contains the main determinants for
FIV SU binding to CXCR4, we do not exclude the possibility that
the V2 and V4 loops in some way contribute to the interaction
with CXCR4. X-ray crystallography or nuclear magnetic
resonance analysis needs to be carried out in order to further
define structural involvement in receptor interactions. It will also
be of interest to determine whether the N44 region of SU interacts
with the extracellular loop-2 (ECL-2) or other parts of CXCR4.
The present study demonstrates the general features of the
CXCR4-binding surface of SU and the relatively subtle adjust-
ments in the V3 loop of FIV isolates that can impact on receptor
binding. The identification of structures important for receptor
binding of FIV isolates should help in defining targets for blocking
virus entry. Moreover, the information contributes valuable
knowledge for the use of the FIV/cat system as a small animal
model for HIV/AIDS.
Materials and Methods
Cell lines, virus and reagents
The interleukin-2 (IL-2)-independent feline lymphoma cell line
3201 was obtained from William Hardy (Sloan-Kettering
Memorial Hospital, NY). The primary IL-2-dependent T-cell line
104-C1 is a clone isolated from feline PBMCs by limiting dilution
and was a gift from Chris K. Grant (Custom Monoclonal
Antibodies, Intl.). CrFK cells were obtained from the ATCC
(Rockville, Md.). Gfox cells are CXCR4
+ Crandell feline kidney
(CrFK) cells stably transfected with feline CD134 and thus
productively infectable by field strains of FIV [6,45]. CHO-K1
and 293T cells were obtained from the American Type Culture
Collection (Rockville, MD). Propagation of the above cell lines was
Table 3. Effects of Amino Acid Substitutions in SU on CD134-
binding Ability in 104-C1 Cells.
PPR SU variants AMD 3100
- +
Mock 0.460.0 -
Wild type 100.060.0 92.463.6
S392A 68.667.8 52.760.9
S392M 50.369.4 53.362.6
S392T 60.863.2 55.362.5
S393A 98.464.9 91.061.8
S393M 77.967.8 75.660.1
S393T 81.067.8 78.664.6
W394A 82.567.9 76.666.1
W394G 77.064.0 73.461.3
W394Y 81.167.5 75.969.8
S392A/S393A/W394A 65.169.1 64.2610.7
R395K 100.468.1 81.169.5
R395N 65.763.7 67.666.0
Q396N 65.263.3 59.866.4
K397R 73.45465.5 64.264.3
R395K/K397R 87.362.5 73.961.2
N398Q 69.066.7 64.867.9
R399K 84.660.0 84.063.8
W400G 56.560.2 61.967.4
W400Y 74.760.7 78.161.6
W394G/W400G 52.368.4 57.164.6
Binding of FIV PPR SU-Fc of wild type and mutants to 104-C1 was analyzed by
FACS in the presence and absence of AMD3100. Cells were incubated with SU-
Fc of wild type or mutants for 1 h at the room temperature or pre-treated with
AMD3100 for 0.5 h before the addition of SU-Fc. Results are indicated as
mean6SD of three independent determinations. Values for mutants are
percentages of the mean fluorescence intensity of wild type SU, which is
regarded as 100%.
doi:10.1371/journal.pone.0010689.t003
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lymphocytic SupT1 cells expressing CXCR4 were acquired from
Bruce Torbett (The Scripps Research Institute) and cultivated in
DMEM medium supplemented with 10% fetal bovine serum
(FBS, Invitrogen, Carlsbad, CA), 2 mM L-glutamine (Sigma, St.
Louis, MO), non-essential amino acids (Sigma), Penicillin-
Streptomycin 100 u/ml and 100 mg/ml respectively (Invitrogen).
The FIV strain used in the present study was FIV-PPR, a
molecularly cloned clade A primary isolate of the FIV San Diego
isolate [28]. Human specific anti-CXCR4 antibody 12G5 [38–40]
was obtained from BD Biosciences (Franklin Lakes, NJ), feline
anti-CXCR4 monoclonal antibody was purchased from R&D
Systems, Inc (Minneapolis, MN), which is highly specific for feline
CXCR4. CrFK cells transfected with feline CXCR4 could be
stained brightly with the feline anti-CXCR4 antibody, while CrFK
cells transfected with human CXCR4, were not stained by this
antibody, supporting a high degree of antibody specificity. In
addition, the staining for feline CXCR4 transfected CrFK cells
could be inhibited by feline CXCR4 siRNA treatment (see Figure
S1). Rabbit anti-feline CD134 antibody was homemade [6].
Rabbit anti-His antibody was obtained from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). V3-specific monoclonal
antibodies (mAbs) were generated by immunizing mice with SU-
Fc, as reported previously [36,42,43]. Rigorous tests for relative
affinity have not been carried out, but an evaluation of the
antibody neutralizing activity was performed, with IC50 values
around 10 mg/ml. AMD3100 was purchased from Sigma.
Construct, expression, and purification of His-tagged V3
peptide
The 41 aa sequence corresponding to V3 loop of FIV PPR was
cloned by using primers 59-GTGGATGGTGGAATCA-
TATGGCCTATTATAACAG-39 to insert an NdeI site on the 59
side of V3, and 59-CTCCTGGAATTCTCATTGCAAAAGTT-
TAATTATG-39 to insert an EcoRI site on the 39 side of V3. The
completed PCR reaction was digested with DpnI for 1 hour at 37uC
before gel purification by utilization of the Quick Gel Extraction Kit
(Invitrogen). The V3 region was ligated into the TOPO cloning
vector pCR2.1 (Invitrogen) and transformed into Top10 cells.
Colonies were screened by using the same primers described as
above, and colonies containing the expected sequence were
midiprepped (Invitrogen). Then, pCR2.1 TOPO-V3 along with
pET28a was cut with NdeI and EcoRI following New England
Biolab’s recommendations. The V3 insert and pET28a vector were
gelpurifiedpost restriction digestion and ligated together before being
transformed into Top10 for selection. V3 in frame with a 6x His-tag
was selected and transformed into competent Escherichia coli Rosetta
(DE3) pLysS cells (Novagen). Isopropyb-D-thiogalactoside induced
protein expression was scaled up, and purification was carried out by
using three rounds of Ni-affinity chromatography.
Recombinant SU proteins
Mutations were introduced into a pRSC-GS-SU-Fc expressor
plasmid and performed by using the QuikChange site-directed
mutagenesis strategy (Stratagene, La Jolla, CA) as recommended
by the manufacturer. The presence of the desired mutations and
the absence of any other mutation was confirmed by DNA
sequencing. Mutated plasmids were then used for production of
stable CHO-K1 cell lines, as previously described [48]. Single
colonies with high expression of the desired Fc-tagged proteins
were selected by single colony disk (Labcor Products,Inc, San
Diego, CA). SU-Fc fusion proteins (adhesins) with the desired
mutations or wild type SU-Fc from stable CHO cell supernatants
were purified by affinity chromatography over protein A-
Sepharose 4FastFLow beads (GE Healthcare, Piscataway, NJ)
and eluted in a 100 mM citric acid and 150 mM NaCl solution
(pH 2.1) into 100 ml 1 M Tris (pH 11.0). The elutions were then
washed and concentrated three times with 1X PBS in a 100,000
MWC Amicon Ultra centrifugal filter device (Millipore, Bilerica,
MA). After that, purified Fc-tagged fusion proteins were quantified
using a human IgG ELISA quantitation kit (Bethyl Laboratories,
Inc, Montgomery, TX), and the process was performed according
Figure 6. Virus entry analysis of b-gal-expressing pseudovirions with SU of wild type or mutants in Gfox cells. Supernatants from 293T
cells transfected with constructs expressing either wild type or mutant SUs were analyzed for RT activity 48 h after transfection and RT values were
normalized for wt and mutants. Pseudovirions were then used in single-round infections of Gfox cells. pCFIV vector pseudotyped with a deleted
envelope (DEnv) was used to assess the degree of viral entry. A b-gal assay was performed 48 h after infection. Values for mutants are percentages of
the mean relative luminescence units of wild type SU set at 100%. Results are means6SD for three independent determinations.
doi:10.1371/journal.pone.0010689.g006
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relative quantitation of proteins was confirmed by western blot
analysis.
Western blot analysis
100 ng of purified Fc-tagged fusion proteins was loaded on an 8
to 16% sodium dodecyl sulfate (SDS)-polyacrylamide gel (PAGE,
Invitrogen) and transferred to a nitrocellulose membrane. The
membrane was blocked with blotto for 30 minutes before the
exposure to horseradish peroxidase (HRP) conjugated goat anti-
human IgG (Fc- specific) antibody (MP Biomedicals, Solon, Ohio,
1:1000 dilution) for 1 h at room temperature. Then, the
membrane was washed with PBST (phosphate-buffered saline
containing 0.05% Tween 20) for 10 minutes, 3 times, before a final
rinse with water. The signal was detected by enhanced
chemiluminescence using SuperSignal West Dura Extended
Duration Substrate (Thermo Scientific, Rockford, IL).
Flow cytometry analysis
Binding of SU-Fc fusion proteins or Fc (negative control) to the
surfaces of 3201, 104-C1, or Sup-T1 cells was analyzed by flow
cytometry, using a phycoerythrin-conjugated goat anti-human
IgG1 Fc antibody (MP Biomedicals, Aurora, OH) and FLOWJO
software (Tree Star, San Carlos, CA). CXCR4-specific binding
was confirmed by pre-treatment of cells with the CXCR4
inhibitor, AMD3100 at the indicated concentration for 0.5 h at
25uC, followed by the incubation with SU-Fc fusion proteins for
1 h at 25uC. For His-tagged V3 peptide binding studies, the
peptide was incubated at 25uC for 1 h, then competed with wild
type SU-Fc fusion proteins for 1 h at 25uC. Receptor expression
was measured by using anti-CXCR4 or CD134 antibody
incubated with cells for 1 h at 25uC, followed by incubation with
phycoerythrin-conjugated goat anti-mouse (CXCR4) or goat anti-
rabbit (CD134) antibody for 45 min at 25uC.
Virus entry assay
Cytomegalovirus_FIV hybrid vectors (pCFIV) [6,45,49] pseu-
dotyped with either wild type FIV-PPR envelope (PPR Env) genes
or mutants substituted by specific amino acids were cotransfected
with a beta-galactosidase (b-gal)-expressing vector [6,45,49] in
293T cells. Two days later, viral supernatants were collected and
each pseudovirion was assessed for the level of reverse transcrip-
tase (RT). RT values were normalized before performing a single
round infection assay in Gfox cells [45]. After 48 h of infection, b-
Table 4. Mapping of binding sites of V3-specific SU MAbs by
ELISA, using wild type and mutated SU-Fc proteins.
PPR SU variants V3 antibodies
SU1-5 SU1-7 SU1-10 SU1-30
Wild type 100.060.0 100.060.0 100.060.0 100.060.0
S392A 84.863.8 85.563.4 89.762.4 98.668.0
S392M 82.062.2 89.064.7 86.066.8 98.063.4
S392T 85.263.3 88.863.5 90.267.2 90.466.7
S393A 79.862.2 96.465.6 95.864.1 80.864.0
S393M 89.665.0 93.863.3 92.861.0 89.466.6
S393T 87.769.0 91.563.4 99.063.2 86.167.3
W394A 84.861.5 94.864.9 90.665.5 2 23.560.7
W394G 82.862.6 95.465.4 94.663.8 9 9.065.4
W394Y 84.466.0 94.660.2 93.163.3 3 34.864.9
S392A/S393A/W394A 74.762.2 88.066.0 84.067.1 1 13.261.0
R395K 89.664.9 95.663.8 88.663.0 98.065.5
R395N 88.665.7 94.568.7 84.962.0 90.564.6
Q396N 93.665.2 94.662.8 86.663.0 93.464.4
K397R 100.065.6 91.562.9 96.865.4 90.561.2
R395K/K397R 91.664.8 89.267.6 92.868.6 93.167.8
N398Q 96.163.0 96.860.9 93.261.2 61.362.4
R399K 99.664.8 9 9.962.2 99.866.6 91.166.6
W400G 79.162.8 4 4.860.0 87.962.7 75.261.5
W400Y 84.667.7 58.063.0 84.065.3 80.066.4
W394G/W400G 79.065.2 7 7.560.2 78.869.0 1 11.562.2
a. Binding of FIV SU-Fc of wild type and mutants to V3-specific MAbs detected
by ELISA. V3-specific MAbs were incubated with SU-Fc of wild type or mutants
for 1 h at the room temperature. For measurement of the binding of antibodies
to the wild type and mutant SU-Fc, various dilutions of SU-Fc were performed in
a pilot experiment to ensure that binding occurred in the linear range of the
assay. Results are indicated as mean6SD of three independent determinations.
Values for mutants are percentages of the mean optical density value of wild
type SU, which is regarded as 100%.
b. Values in bold represent loss of specific antibody reactivity to a given mutant.
doi:10.1371/journal.pone.0010689.t004
Table 5. Mapping of binding sites of V3-specific SU MAbs by
ELISA, using wild type and mutated SU-Fc proteins.
PPR SU variants V3 antibodies
SU2-4 SU2-5 SU2-10
Wild type 100.060.0 100.060.0 100.060.0
S392A 91.267.0 95.463.8 96.166.2
S392M 95.867.6 95.760.5 97.762.7
S392T 93.660.8 90.563.5 84.764.0
S393A 99.568.6 95.663.1 92.565.4
S393M 86.560.8 98.465.8 91.866.2
S393T 92.863.8 91.066.7 94.766.3
W394A 96.064.1 97.466.2 92.065.0
W394G 85.865.2 91.666.5 89.665.3
W394Y 90.466.7 96.164.2 88.564.2
S392A/S393A/W394A 81.165.5 86.563.0 84.566.9
R395K 90.666.1 86.063.2 84.364.9
R395N 72.365.2 76.963.7 85.462.7
R395K/K397R 94.867.6 94.261.4 100.862.1
Q396N 95.567.3 95.966.0 97.962.8
K397R 84.263.6 95.161.9 89.566.9
N398Q 92.669.2 98.964.2 92.264.3
R399K 87.566.5 95.268.1 100.969.0
W400G 5 5.460.7 7.962.0 52.862.6
W400Y 66.461.3 43.563.1 63.765.6
W394G/W400G 5 5.760.9 13.563.1 42.863.7
a. Binding of FIV SU-Fc of wild type and mutants to V3-specific MAbs detected
by ELISA. V3-specific MAbs were incubated with SU-Fc of wild type or mutants
for 1 h at the room temperature. For measurement of the binding of antibodies
to the wild type and mutant SU-Fc, various dilutions of SU-Fc were performed in
a pilot experiment to ensure that binding occurred in the linear range of the
assay. Results are indicated as mean6SD of three independent determinations.
Values for mutants are percentages of the mean optical density value of wild
type SU, which is regarded as 100%.
b. Values in bold represent loss of specific antibody reactivity to a given mutant.
doi:10.1371/journal.pone.0010689.t005
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minescent reporter gene assay (Applied Biosystems Inc, Bedford,
MA) according to the manufacturer’s guidelines.
Micro-RT activity assay
Micro-RT activity assay was performed as previously described
[9,36,48]. Briefly, 50 ml of cell-free supernatant together with 10 ml
of lysis buffer (0.75 M KCl, 20 mM dithiothreitol, 0.5% Triton X-
100) was incubated at room temperature for 10 minutes. Then,
40 ml of a mixture containing 125 mM Tris-HCl (pH 8.1),
12.5 mM MgCl2, 1.25 mg poly(rA)-poly(dT)12–18 (Amersham
Biosciences, Piscataway, NJ) and 1.25 mCi of [
3H]dTTP (DuPont,
Boston, MA) was added to the sample followed by 2 h of
incubation at 37uC. The measurement of RT activity was
previously described [48].
Enzyme-linked immunosorbent assay (ELISA)
Immulon II HB plates (Thermo, Milford, MA) were coated
overnight with 1 mg of anti-V3 antibodies in PBS (pH 7.2). Then
the plate washed twice with PBS and dried. 100 ng of purified SU-
Fc fusion proteins of wild type or mutants was diluted in 100 mlo f
ELISA buffer (0.15 M NaCl, 0.05 M Tris-HCl, 1 mM EDTA, 3%
bovine serum albumin fraction V, 3.5% fetal calf serum, and
0.05% Tween 20, pH 7.4), then added to appropriate wells. After
1.5 h incubation, the plate was washed three times with PBS and
dried. HRP-conjugated goat anti-human IgG antibody diluted in
ELISA buffer was added to every well and incubated for 1 h. After
the same washing procedure, enzyme substrate reaction was
performed for 10 min by using OPD as substrate, followed by the
addition of stop solution of 2M H2SO4. The OD value was read at
493 nm using a microtiter plate reader. All operations were
carried out at room temperature.
Supporting Information
Figure S1 Specificity of anti-feline CXCR4 antibody. (A).
CXCR4 expression on the cell surface was detected by FACS
analysis in CrFK (left panel), feline CXCR4-transfected CrFK
(middle panel), and human CXCR4-transfected CrFK (right
panel) cells, respectively. (B). FACS analysis of the CXCR4
expression in the feline CXCR4-transfected CrFK cells with (left
panel) or without (right panel) pretreatment with CXCR4-specific
siRNA. Cells were stained with anti-feline CXCR4 antibody.
Black line indicates background staining, blue or red line indicates
CXCR4 staining.
Found at: doi:10.1371/journal.pone.0010689.s001 (0.16 MB TIF)
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